BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, January 12, 2026
Home » Authors » Haky Moon

Haky Moon

Articles

ARTICLES

Israel looking to be a key player in global digital health care market

March 31, 2017
By Haky Moon

In drive to reduce health care costs, Asia's wearable device market poised to top $2.2B

March 27, 2017
By Haky Moon

South Korea revises rules for med tech's UDIs

March 13, 2017
By Haky Moon

U.K. court favors Fujifilm Kyowa Hakko Kirin in Humira patent litigation

March 7, 2017
By Haky Moon

HONG KONG – In a final ruling, the U.K.'s High Court of Justice ruled in favor of Tokyo-based Fujifilm Kyowa Kirin Biologics Co. Ltd. in a patent revocation proceeding against Abbvie Inc., which has been fighting to protect its blockbuster Humira (adalimumab).


Read More

U.K. court favors Fujifilm Kyowa Hakko Kirin in Humira patent litigation

March 7, 2017
By Haky Moon
HONG KONG – In a final ruling, the U.K.'s High Court of Justice ruled in favor of Tokyo-based Fujifilm Kyowa Kirin Biologics Co. Ltd. in a patent revocation proceeding against Abbvie Inc., which has been fighting to protect its blockbuster Humira (adalimumab).
Read More

Samsung's biosimilars come to fruition despite scandals, company says

Feb. 22, 2017
By Haky Moon
HONG KONG – It is a tumultuous year for Korean conglomerate Samsung, whose group chief Jay Y. Lee was arrested Friday in connection to a corruption scandal, and Samsung Biologics Co. Ltd., the company's contract manufacturer arm of biologic drugs, coming under scrutiny with allegations of being involved in unlawful accounting practices.
Read More

Samsung's biosimilars come to fruition despite scandals, company says

Feb. 21, 2017
By Haky Moon
HONG KONG – It is a tumultuous year for Korean conglomerate Samsung, whose group chief Jay Y. Lee was arrested Friday in connection to a corruption scandal, and Samsung Biologics Co. Ltd., the company's contract manufacturer arm of biologic drugs, coming under scrutiny with allegations of being involved in unlawful accounting practices.
Read More

India finally introduces med-tech regulations after decade of wrangling

Feb. 17, 2017
By Haky Moon

South Korea seeks to bolster local med-tech industry with fresh infusion of funding

Feb. 8, 2017
By Haky Moon

As Nesp patent nears expiration, Kirin sets up new biosimilar firm

Feb. 8, 2017
By Haky Moon
HONG KONG – It is not surprising that Tokyo-based Kyowa Hakko Kirin Co. Ltd. wants to hold on to Nesp (darbepoetin alfa), an erythropoiesis-stimulating agent used as a treatment for improving renal anemia, when the patent expires in 2019.
Read More
View All Articles by Haky Moon

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 9, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld Science
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • LINC01116 has prognostic value in lung cancer, study shows

    BioWorld Science
    Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
  • Icons representing scientific research

    Science in 2025: the best of the rest

    BioWorld Science
    A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing